Early Experience With Brolucizumab for Neovascular Age-Related Macular Degeneration

This case series reports clinical outcomes after intravitreous injection of brolucizumab, 6 mg, for neovascular age-related macular degeneration.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research